Delivery Order SPE2DX22D0010-SPE2D823FEP97
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The $3,108.13 firm fixed-price delivery order is for the supply of Oxymorphone HCL ER Tablets, 7.5mg. This order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025, which enables DLA Troop Support Medical to efficiently procure a comprehensive...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,072.10 firm fixed-price delivery order is for 4566339699 - Oxymorphone HCL ER 10 MG Tablets, 100 per bottle. The contract has a period of performance through November 6, 2024 and was not designated with a set-aside requirement. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This is a delivery order awarded by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for Oxymorphone HCL ER Tablets 30mg. The $7,186.27 firm fixed-price contract has an ultimate completion date of December 1, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical for a...
- This federal contract award was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,824.02 firm fixed-price delivery order is for the supply of Oxymorphone HCL ER Tablets, 7.5 mg, with a period of performance through February 10, 2025. The contract has no set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, provides for the delivery of Oxymorphone HCL ER Tabs 40mg to the Defense Logistics Agency (DLA) Troop Support Medical. The $5,566.16 firm fixed price contract has a completion date of June 21, 2024. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,325.87 Firm Fixed Price Delivery Order is for the supply of Oxymorphone HCL ER Tablets 40mg, a pain management medication. The award has no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of oxymorphone HCL ER tablets, a pharmaceutical product used for pain management. The award, valued at $6,771.72, is a firm fixed-price delivery order with a completion date of December 11, 2023. The contract does not have a set-aside designation, indicating it was awarded through full and open competition....
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $5,417.79, is for the delivery of oxymorphone hydrochloride extended-release tablets with a completion date of February 4, 2025. The contract is a firm fixed-price Delivery Order, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $9,327.87 firm fixed-price delivery order is for the supply of 10 milligram oxymorphone hydrochloride tablets, a pain medication. The award has an ultimate completion date of December 6, 2021 and was not set aside for any specific business category. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery...
- This federal contract award, valued at $3,227.16, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Oxymorphone HCL ER Tablets, 20mg, a pain management medication. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued at $999,999,999 and running through...
- SPE2DX22D0010Indefinite Delivery Contract
- SPE2DX22D0010-SPE2D823FEP97Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,212.55 firm fixed-price delivery order is for the supply of Oxymorphone HCL ER Tablets, 10mg, with a completion date of February 21, 2023. The contract is not designated with a set-aside. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate $750,000 IDC with the Department of Justice Federal Bureau of Investigation through May 2024, covering similar medical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 2/20/23 |